Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC CEF: Pharmacokinetics of High-dose Ceftobiprole in Severe Community-acquired Pneumonia
NCT04171674Completed
- Sponsor
- CHU Nîmes
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of ceftobiprole medocaril in community acquired pneumonia (CAP), sponsored by CHU Nîmes. Primary endpoints: Plasma concentration of ceftobiprole at Day 3 and Maximum plasma concentration at Day 1. Started Apr 2021; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT04171674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171674.